A skincare company’s chief executive has admitted mail fraud and federal food-and-drug violations in a case involving injectable products sold to consumers. The plea includes an agreement to forfeit $800,000, turning a product-safety prosecution into a direct financial warning. A polished website and medical-sounding label cannot substitute for federal approval or a traceable supply chain.
The plea covers fraud and unapproved products
On July 31, Scalpa president and CEO Bryce Cleveland pleaded guilty to mail fraud, introducing an adulterated device into interstate commerce, and introducing an unapproved new drug into interstate commerce. He also agreed to forfeit $800,000 and pay restitution for the full scope of the criminal conduct.
The Justice Department release says the court has not yet imposed a final prison sentence. Cleveland agreed to a sentencing range of four to eight years, but that negotiated range remains distinct from the completed guilty plea and forfeiture agreement. The headline’s financial claim rests on the latter, not on predicting what the judge will ultimately order.
Free retirement updates: Scam calls targeting retirees change every week. Our free Retirement Shield newsletter flags the ones going around and the one tell that stops each. Sign up free.
ScalpaJECT and Scalpatox drove the case
Prosecutors said Scalpa marketed products intended to alter the body’s structure and function. From 2018 through 2020, Cleveland promoted and delivered devices including ScalpaJECT Hyaluronic Acid and the Hyaluron Pen while falsely representing that they were outside FDA regulation. He also introduced an unapproved botulinum toxin drug called Scalpatox into commerce.
These were not ordinary jars of moisturizer. Injectable devices and drugs bypass barriers that protect the body from toxins and microorganisms. That delivery route raises the stakes for consumers who may assume a product sold through a professional-looking channel has undergone the same review as an FDA-approved prescription product.
FDA warnings make the safety risk current
The product problem extends beyond this criminal case. In November 2025, the FDA warned 18 online sellers over unapproved and misbranded botulinum toxin products. The agency said it was aware of adverse events, including botulism symptoms, and noted that approved botulinum toxin drugs carry the agency’s most serious boxed warning.
FDA-approved versions require a prescription and should come from an authorized source through a licensed, trained provider. The agency advises immediate medical attention for symptoms such as trouble swallowing or breathing after an injection. Those safeguards matter because counterfeit, contaminated or improperly stored injectables can look convincing while carrying risks that a shopper cannot assess from packaging.
Price is not the only exposure
A lower online price may appear to create savings, particularly for older consumers living on fixed income. The real cost can include follow-up treatment, emergency care and a product that provides no expected benefit. Money sent to an overseas or opaque seller can also be difficult to recover once a shipment arrives or a card charge is disputed.
The FDA’s counterfeit-medicine guidance advises consumers to obtain prescription drugs through state-licensed pharmacies and to treat altered packaging, unexpected side effects or unfamiliar labeling as warning signs. A provider should be able to identify the exact product, manufacturer and source before an injection occurs.
The forfeiture follows the money
Forfeiture removes proceeds tied to criminal conduct; restitution addresses losses suffered by victims. The plea agreement includes both concepts, though the Justice Department specified the forfeiture amount at $800,000 and described restitution as covering the entire scope of the conduct. A final restitution calculation may therefore involve additional court work.
The immediate source-led conclusion is narrower and stronger than speculation about sentencing. A corporate officer admitted the offenses on July 31 and agreed to surrender $800,000. For consumers comparing cosmetic injectables, the case supplies a costly reason to verify federal approval and the seller’s supply chain before money or medicine changes hands.
Approval can be checked at the product level, not by accepting a seller’s statement that an ingredient is commonly used. A legitimate provider should be able to show the sealed vial or device, identify the manufacturer and describe the product being administered. Lot numbers and packaging can be recorded in the medical file so that a later safety alert can be matched to the exact treatment.
Payment method provides another warning signal. An online seller that insists on a wire, cryptocurrency or cash-equivalent payment is removing the ordinary dispute protections attached to a credit card. A medically risky product paired with an irreversible payment deserves more scrutiny, not a quicker decision because the price is temporarily reduced.
Patients who experience an adverse reaction can report it through FDA MedWatch in addition to seeking medical care. A report helps regulators connect symptoms with a product, lot or seller, while receipts and photographs preserve evidence for a charge dispute or restitution claim. Waiting for sentencing does not improve that record; the important documents are created at the time of purchase and treatment.
The $800,000 forfeiture also does not establish what any individual consumer will receive. Forfeited proceeds move through federal processes, and restitution depends on court orders and verified losses. Anyone approached by a private “claims agent” promising a share in exchange for a fee should verify the case through the Justice Department rather than paying to join a recovery list.
This article was researched and drafted with AI assistance and reviewed against the linked primary sources.
More Financial Reading
- What really happens to your joint savings account when you die?
- Adding someone to your bank account: tax traps and smart moves
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
